Ticlopidine - Analogs & derivatives
Research News and Information

Sunday, November 22, 2009

Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients.

13 Oct 2009 A low response to clopidogrel has been associated with an increased risk of stent thrombosis. However, the definition of a nonresponse to clopidogrel remains controversial, and different tests have been used to assess the clopidogrel response. The ... Read more...

Clinical benefit of early reperfusion therapy in patients with ST-elevation myocardial infarction usually excluded from randomized clinical trials (results from the Maximal Individual Therapy in Acute Myocardial Infarction Plus [MITRA Plus] registry).

13 Oct 2009 Randomized clinical trials (RCTs) usually enroll selected patient populations that may not be representative for patients seen in everyday practice. Therefore, concerns have been raised regarding their external validity. For the present study we ... Read more...

Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial.

4 Oct 2009 OBJECTIVES: Our aim was to determine whether a 600-mg loading dose of clopidogrel compared with 300 mg results in improved clinical outcomes in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary ... Read more...

Latest indexed articles for 'Ticlopidine - Analogs & derivatives'

These are the very latest articles for this heading:

• Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients. 13 Oct 2009
• Clinical benefit of early reperfusion therapy in patients with ST-elevation myocardial infarction usually excluded from randomized clinical trials (results from the Maximal Individual Therapy in Acute Myocardial Infarction Plus [MITRA Plus] registry). 13 Oct 2009
• Routine early angioplasty after fibrinolysis. 6 Oct 2009
• Hunting for the "sweet spot" in P2Y12 receptor blockade. 4 Oct 2009
• Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. 4 Oct 2009
• Antiplatelet agents used for early intervention in acute coronary syndrome: myocardial salvage versus bleeding complications. 29 Sep 2009
• Timing of clopidogrel loading before percutaneous coronary intervention in clopidogrel-naive patients with stable or unstable angina: a comparison of two strategies. 29 Sep 2009
• Randomized controlled trial of aspirin and clopidogrel versus aspirin and placebo on markers of smooth muscle proliferation before and after peripheral angioplasty. 29 Sep 2009
• Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. 27 Sep 2009
• Clopidogrel plus aspirin in atrial fibrillation. 22 Sep 2009
• Clopidogrel plus aspirin in atrial fibrillation. 22 Sep 2009
• Clopidogrel plus aspirin in atrial fibrillation. 22 Sep 2009
• Clopidogrel plus aspirin in atrial fibrillation. 22 Sep 2009
• Clopidogrel plus aspirin in atrial fibrillation. 22 Sep 2009
• Clopidogrel plus aspirin in atrial fibrillation. 22 Sep 2009
• Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. 20 Sep 2009
• Prasugrel (Effient) vs. clopidogrel (Plavix). 5 Sep 2009
• Platelet-directed therapies and coronary artery bypass grafting. 5 Sep 2009
• Challenges in oral antiplatelet therapy: ST-segment elevation myocardial infarction. 5 Sep 2009
• [New thrombocyte inhibitor. Fewer ischemic complications in acute coronary syndrome] Sep 2009

See a longer list of these articles.

Technical information about 'Ticlopidine'

Definition: Ticlopidine is an effective inhibitor of platelet aggregation. The drug has been found to significantly reduce infarction size in acute myocardial infarcts and is an effective antithrombotic agent in arteriovenous fistulas, aorto-coronary bypass grafts, ischemic heart disease, venous thrombosis, and arteriosclerosis.

Chemical name: Thieno(3,2-c)pyridine, 5-((2-chlorophenyl)methyl)-4,5,6,7-tetrahydro-

Registry Number: 55142-85-3

Descriptor UI: D013988

Alternative terms: Ticlopidine; Ticlopidine Hydrochloride; Hydrochloride, Ticlopidine; Ticlodix; Ticlodone; 53-32C; 53 32C; 5332C; Ticlid;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Fibrinolytic Agents; Platelet Aggregation Inhibitors;

Tree Number: D02.886.778.834; D03.383.903.834;

History Note: 87